Inventor · disambiguated record
Yukimi Sakoda
Also filed as: SAKODA YUKIMI
8 granted patents·16 pending applications·27 citations·filing 2015–2025
83Inventor score
Top patents by PatentIndex Score
24 records- 0194US11931381B2Immunocompetent cell and expression vector expressing regulatory factors of immune functionUNIV YAMAGUCHI·Filed 2022·Granted Mar 19, 2024·3 cites·20 claims
- 0293US10316102B2Car expression vector and car-expressing T cellsUNIV YAMAGUCHI·Filed 2015·Granted Jun 11, 2019·12 cites·19 claims
- 0391US11337997B2Immunocompetent cell and expression vector expressing regulatory factors of immune functionUNIV YAMAGUCHI·Filed 2017·Granted May 24, 2022·5 cites·19 claims
- 0491US10906984B2CAR expression vector and CAR-expressing T cellsUNIV YAMAGUCHI·Filed 2019·Granted Feb 2, 2021·5 cites·32 claims
- 0586US10781249B2Anti-GPC3 antibodyUNIV YAMAGUCHI·Filed 2019·Granted Sep 22, 2020·2 cites·8 claims
- 0682US12129291B2Anti-GPC3 antibodyUNIV YAMAGUCHI·Filed 2023·Granted Oct 29, 2024·0 cites·15 claims
- 0782US2024307451A1Immunocompetent cell and expression vector expressing regulatory factors of immune function, and chimeric antigen receptorNOILE IMMUNE BIOTECH INC·Filed 2024·Application pending·0 cites
- 0881US2024226157A1Immunocompetent Cell and Expression Vector Expressing Regulatory Factors of Immune FunctionUNIV YAMAGUCHI·Filed 2024·Application pending·0 cites
- 0972US2024139248A1Immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, il-7 and ccl19NOILE IMMUNE BIOTECH INC·Filed 2024·Application pending·0 cites
- 1070US2024269174A1Enhancer for t-cells or b-cells having memory function, malignant tumor recurrence inhibitor, and inducer for inducing memory function in t-cells or b-cellsUNIV YAMAGUCHI·Filed 2023·Application pending·0 cites
- 1168US11617765B2Enhancer for T-cells or B-cells having memory function, malignant tumor recurrence inhibitor, and inducer for inducing memory function in T-cells or B-cellsUNIV YAMAGUCHI·Filed 2018·Granted Apr 4, 2023·0 cites·18 claims
- 1265US2025268942A1Isolated immune cell expressing a receptor, interleukin-7, and chemokine (c-c motif) ligand 19NOILE IMMUNE BIOTECH INC·Filed 2025·Application pending·0 cites
- 1365US2021253726A1Car expression vector and car-expressing t cellsUNIV YAMAGUCHI·Filed 2020·Application pending·0 cites
- 1463US11718663B2Anti-GPC3 antibodyUNIV YAMAGUCHI·Filed 2018·Granted Aug 8, 2023·0 cites·18 claims
- 1561US2025332195A1Chimeric antigen receptor, cell expressing said receptor, pharmaceutical composition including said cell, method for producing said cell, and polynucleotide or vector including nucleotide sequence encoding said chimeric antigen receptorNOILE IMMUNE BIOTECH INC·Filed 2022·Application pending·0 cites
- 1661US2025121002A1ANTI-EGFRviii ANTIBODY, POLYPEPTIDE, CELL CAPABLE OF EXPRESSING SAID POLYPEPTIDE, PHARMACEUTICAL COMPOSITION COMPRISING SAID CELL, METHOD FOR PRODUCING SAID CELL, AND POLYNUCLEOTIDE OR VECTOR COMPRISING NUCLEOTIDE SEQUENCE ENCODING SAID POLYPEPTIDENOILE IMMUNE BIOTECH INC·Filed 2022·Application pending·0 cites
- 1758US2024400718A1ANTIBODY BINDING TO LINKER OF scFv OR LIKENOILE IMMUNE BIOTECH INC·Filed 2022·Application pending·0 cites
- 1858US2020323920A1Immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, il-7 and ccl19NOILE IMMUNE BIOTECH INC·Filed 2018·Application pending·0 cites
- 1956US2021122831A1Chimeric antigen receptorNOILE IMMUNE BIOTECH INC·Filed 2018·Application pending·0 cites
- 2055US2023322898A1Pharmaceutical composition comprising cell expressing chimeric receptorCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 2152US2022324975A1Antibody cleavage site binding moleculeCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 2251US2022143094A1Chimeric receptor that recognizes engineered site in antibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 2350US2023071098A1Anti-gpc3 single-chain antibody-containing carNOILE IMMUNE BIOTECH INC·Filed 2019·Application pending·0 cites
- 2450US2022401480A1Drug for Treating Cancer, Combination Drug, Drug Composition, Immune Responsive Cell, Nucleic Acid Delivery Vehicle, and ProductNOILE IMMUNE BIOTECH INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yukimi Sakoda files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →